"Orange Book" Patent Abuses Could Be Addressed By FDA Limitations - Atty.
This article was originally published in The Tan Sheet
Executive Summary
FDA should issue regulations limiting "Orange Book" patent listings by brand name pharmaceutical companies to those patents that claim the listed drug or approved method of use, attorney David Weeda suggested at the Warburg Dillon Read Specialty Pharmaceutical Conference in New York City May 26. Weeda, a partner at the D.C. firm Olsson, Frank and Weeda, is a former FDA associate chief counsel.